 
        
        
         
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 靶点 | 
 | 
| 描述 | The histone acetyltransferase p300/CBP is a transcriptional coactivator involved in many regulatory pathways during tumorigenesis. C646 is a selective and competitive p300 inhibitor with a Ki value of 400nM. Treatment of C3H 10T1/2 mouse fibroblasts with C646 (25μM) resulted in a reduction in the levels of histone H3 and H4 acetylation. C646 at a concentration of 25μM also inhibited TSA-induced acetylation in mouse fibroblasts. C646 at 10μM was capable of reducing 3H-thymidine incorporation in several human cancer cell lines. The IC50 value of C646 for the growth of melanoma cell line WM983A was 10-20μM[3] The suppression of P300 by C646 via intraperitoneal injection (30nmol/g/day for two weeks) reduced the level of blood glucose, rescued impaired autophagic flux, and resulted in an 18.5% increase in muscle mass in db/db mice.[4] | 
| 作用机制 | C646 is a competitive, highly selective inhibitor of p300 versus other acetyltransferases.[3] | 
| Concentration | Treated Time | Description | References | |
| Porcine aortic valve interstitial cells (pAVICs) | 10 μM | 3 days | C646 treatment significantly reduced calcium deposition, decreased ALP activity, and reduced the expression of osteogenic marker genes, indicating that C646 can attenuate high-calcium/high-phosphate-induced calcification. | Exp Mol Med. 2019 Jul 10;51(7):1-14. | 
| Adult mouse primary cardiac fibroblasts (ACFs) | 3 μM | 24 h | Inhibit the acetyltransferase activity of P300 and observe the effect of C646 on fibroblast activation. Results showed that C646 pretreatment reversed CAR3 deficiency-induced suppression of fibroblast activation and improved cardiac healing and collagen synthesis. | Int J Biol Sci. 2024 Feb 25;20(5):1796-1814. | 
| Drosophila S2 cells | 30 μM | 10 min | CBP inhibition resulted in down-regulation of 3790 genes, indicating the critical role of CBP in transcription regulation | Mol Cell. 2017 Nov 2;68(3):491-503.e5. | 
| HCT116 colon cancer cells | 10 µM | 12 and 96 h | To assess the effects of C646 on the transcriptome of HCT116 cells, it was found that C646 downregulated genes related to the WNT signaling pathway. | Epigenetics Chromatin. 2015 Feb 24;8:9. | 
| PANC1 pancreatic cancer cells | 10 µM | 12 and 96 h | To assess the effects of C646 on the transcriptome of PANC1 cells, it was found that C646 downregulated cell cycle-related genes but did not significantly affect the WNT signaling pathway. | Epigenetics Chromatin. 2015 Feb 24;8:9. | 
| SK-BR-3 | 8 μM | 72 h | C646 prevented PEPD KD from causing K373 acetylation of p53 mutants and induction of p53 target proteins, despite profound PEPD KD. | Commun Biol. 2021 Dec 8;4(1):1373. | 
| MDA-MB-231 | 8 μM | 72 h | C646 prevented PEPD KD from causing K373 acetylation of p53 mutants and induction of p53 target proteins, despite profound PEPD KD. | Commun Biol. 2021 Dec 8;4(1):1373. | 
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6 male mice | Colon cancer transplantation tumor model | Intraperitoneal injection | 30 nmol/g | Every 3 days for 2 weeks | C646 significantly inhibited the growth of CXCL1-overexpressing colon cancer tumors. | Biol Direct. 2022 Nov 25;17(1):34 | 
| Mice | MCA205 fibrosarcoma model | Intraperitoneal injection | 10 mg/kg | Daily, throughout the treatment | To evaluate the antitumor effects of C646 in vivo, results showed that C646 could enhance the antitumor effects of chemotherapy by inducing autophagy. | Cancer Cell. 2016 Jul 11;30(1):147-160 | 
| Mice | Adenine and vitamin D-induced aortic valve calcification model | Subcutaneous injection | 1 mg/kg | Once daily for 14 days | C646 treatment significantly attenuated aortic valve calcification and restored the levels of acetylated histones 3 and 4, indicating that C646 has an inhibitory effect on calcification in vivo. | Exp Mol Med. 2019 Jul 10;51(7):1-14. | 
| Mice | Myocardial infarction model | Intraperitoneal injection | 15 mg/kg | Once daily for 14 consecutive days | Inhibit the acetyltransferase activity of p300 and observe the effect of C646 on cardiac healing and function. Results showed that C646 pretreatment reversed CAR3 deficiency-induced impairment of cardiac healing and function, and improved collagen synthesis. | Int J Biol Sci. 2024 Feb 25;20(5):1796-1814. | 
| Mice | TC1 and AE17 tumor models | Subcutaneous injection | 8.9 mg/kg | Once daily for 3 days | To evaluate the effect of p300i on tumor growth, results showed that p300i significantly inhibited tumor growth. | Nat Med. 2013 Sep;19(9):1173-7. | 
| Dose | Mice: 1 mg/kg[3] (nasal injection), 1 mg/kg[4] (s.c.), 25 mg/kg[5] (i.p.) | 
| Administration | Nasal injection, s.c., i.p. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.25mL 0.45mL 0.22mL | 11.23mL 2.25mL 1.12mL | 22.45mL 4.49mL 2.25mL | |
| CAS号 | 328968-36-1 | 
| 分子式 | C24H19N3O6 | 
| 分子量 | 445.42 | 
| SMILES Code | O=C(O)C1=CC=C(N2N=C(C)/C(C2=O)=C/C3=CC=C(C4=CC(C)=C(C)C=C4[N+]([O-])=O)O3)C=C1 | 
| MDL No. | MFCD01784780 | 
| 别名 | |
| 运输 | 蓝冰 | 
| InChI Key | HEKJYZZSCQBJGB-UNOMPAQXSA-N | 
| Pubchem ID | 1285941 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C | 
| 溶解方案 | DMSO: 12 mg/mL(26.94 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1